Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Curis Inc (CRIS)
NASDAQ:CRIS
Holding CRIS?
Track your performance easily
CRIS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.80 - $17.49
Previous Close$5.93
Volume7.92K
Average Volume (3M)46.95K
Market Cap
$35.10M
Enterprise Value$10.65M
Total Cash (Recent Filing)$28.36M
Total Debt (Recent Filing)$3.56M
Price to Earnings (P/E)―
Beta2.48
Next Earnings
Nov 05, 2024EPS Estimate
-$1.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.24
Shares Outstanding5,978,945
10 Day Avg. Volume41,075
30 Day Avg. Volume46,955
Standard Deviation0.70
R-Squared0.06
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.83
Price to Sales (P/S)3.45
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.04
Enterprise Value/Gross Profit1.09
Enterprise Value/Ebitda-0.23
Forecast
1Y Price Target
$22.00Price Target Upside274.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Curis News
PremiumCompany Announcements
Curis Inc Showcases Leukemia Study Breakthroughs at Conferences
Bulls Say, Bears Say
Bulls Say
Clinical DataData from ASH 2023 showed a CR rate of 60% with ema + ibrutinib in patients from a prior update.
Investor InterestIncreasing investor interest in primary CNS lymphoma (PCNSL) with expected data update from Curis in 15 patients.
Safety ProfileCuris has several advantages over axi-cel, including oral administration and a better safety profile.
Bears Say
Clinical TrialsCuris' response rate might pull back in a larger cohort, potentially reducing significant clinical benefit.
Financial PerformanceCapital constraints will become more apparent in the coming quarters.
Regulatory ChallengesPursuing accelerated path in spliceosome mutant patients will require developing a companion diagnostic.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRIS FAQ
What was Curis Inc’s price range in the past 12 months?
Curis Inc lowest stock price was $3.80 and its highest was $17.49 in the past 12 months.
What is Curis Inc’s market cap?
Currently, no data Available
When is Curis Inc’s upcoming earnings report date?
Curis Inc’s upcoming earnings report date is Nov 05, 2024 which is in 46 days.
How were Curis Inc’s earnings last quarter?
Curis Inc released its earnings results on Aug 01, 2024. The company reported -$2.03 earnings per share for the quarter, missing the consensus estimate of -$1.793 by -$0.237.
Is Curis Inc overvalued?
According to Wall Street analysts Curis Inc’s price is currently Undervalued.
Does Curis Inc pay dividends?
Curis Inc does not currently pay dividends.
What is Curis Inc’s EPS estimate?
Curis Inc’s EPS estimate is -$1.87.
How many shares outstanding does Curis Inc have?
Curis Inc has 5,978,945 shares outstanding.
What happened to Curis Inc’s price movement after its last earnings report?
Curis Inc reported an EPS of -$2.03 in its last earnings report, missing expectations of -$1.793. Following the earnings report the stock price went down -9.854%.
Which hedge fund is a major shareholder of Curis Inc?
Among the largest hedge funds holding Curis Inc’s share is Maverick Capital ltd. It holds Curis Inc’s shares valued at 4M.
---
Curis Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.00 (274.79% Upside)
$22.00 (274.79% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.78%
12-Months-Change
Fundamentals
Return on Equity
-372.68%
Trailing 12-Months
Asset Growth
-40.20%
Trailing 12-Months
Company Description
Curis Inc
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
---
CRIS Earnings Call
Q2 2024
0:00 / 0:00
---
CRIS Stock 12 Month Forecast
Average Price Target
$22.00
▲(274.79% Upside)
Technical Analysis
Bioxcel Therapeutics
―
Fennec Pharmaceuticals
―
Kala Pharmaceuticals
―
TRACON Pharmaceuticals
―
Best Analysts Covering CRIS
1 Year
1 Year Success Rate
6/27 ratings generated profit
1 Year Average Return
+9.25%
reiterated a buy rating 2 months ago
Copying Soumit Roy's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of +9.25% per trade.
---